Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP)
Ironwood Pharmaceuticals, Inc. - Class A (IRWD)
Last ironwood pharmaceuticals, inc. - class a earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ironwoodpharma.com
Company Research
Source: Business Wire
– Patients living with AHP suffer from chronic debilitating symptoms such as severe abdominal pain and often seek care from gastroenterologists – – Alnylam to leverage Ironwood’s leading capabilities in GI to help raise AHP awareness and bring givosiran (if approved) to gastroenterologists and other healthcare practitioners in the U.S. – CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), the leading RNAi therapeutics company and Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI healthcare company, announced today a U.S. GI disease education and promotional agreement for Alnylam’s givosiran, an investigational RNAi therapeutic targeting aminolevulinic acid synthase 1 (ALAS1) for the potential treatment of AHP. Givosiran has received Priority Review designation and Breakthrough Therapy Designation from the U.S. FDA, as well as Orphan Drug Designation in the U.S. The Prescription Drug User Fee Act (PDUFA) date for givosiran is set for February 4, 2020.
Show less
Read more
Impact Snapshot
Event Time:
IRWD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRWD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRWD alerts
High impacting Ironwood Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
IRWD
News
- Here's Why Brown Capital Management Small Company Fund Sold Ironwood Pharmaceuticals (IRWD) [Yahoo! Finance]Yahoo! Finance
- Ironwood Pharmaceuticals to Participate in the Piper Sandler 36th Annual Healthcare ConferenceBusiness Wire
- Ironwood Pharmaceuticals to Participate in the Jefferies London Healthcare ConferenceBusiness Wire
- Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... [Yahoo! Finance]Yahoo! Finance
IRWD
Earnings
- 11/7/24 - Miss
IRWD
Sec Filings
- 12/18/24 - Form 4
- 12/5/24 - Form 8-K
- 11/20/24 - Form 4
- IRWD's page on the SEC website